Details of the Drug Combination

General Information of Drug Combination (ID: DCWQUUE)

Drug Combination Name

ABT-199 Resminostat

Indication

Disease Entry	Status	REF
Diffuse intrinsic pontine glioma	Investigative	[1]

Component Drugs

ABT-199 DM2BLMT

Resminostat DMNE1FR

N.A.

Small molecular drug

High-throughput Screening Result

Testing Cell Line: DIPG25

Zero Interaction Potency (ZIP) Score: 15.12

Bliss Independence Score: 13.247

Loewe Additivity Score: 17.627

LHighest Single Agent (HSA) Score: 19.499

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of ABT-199

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 3	[2]

Indication(s) of Resminostat

Disease Entry	ICD 11	Status	REF
Hepatocellular carcinoma	2C12.02	Phase 2	[3]

Resminostat Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Clinical pipeline report, company report or official report of Abbott Laboratories.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7502).
4	2011 Pipeline of 4SC AG.